Jan Adolfsson

Jan Adolfsson

Auto-generated profile, based on publicly available information

Jan Adolfsson

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in The Lancet
Verified
Journal Article
Open access
MCM P Coleman
M P Coleman
DFD Forman
D Forman
HBH Bryant
H Bryant
JBJ Butler
J Butler
BRB Rachet
B Rachet
IGICBP Module 1 Working Group
ICBP Module 1 Working Group
Cancer survival is a key measure of the effectiveness of health-care systems. Persistent regional and international differences in survival represent many avoidable deaths. Differences in survival have prompted or guided cancer control strategies. This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival. Data from population-based cancer registries in 12 jurisdictions in six countries were provided for 2·4 million adults diagnosed with primary colorectal, lung, breast (women), or ovarian cancer during 1995-2007, with follow-up to Dec 31, 2007. Data quality control and analyses were done centrally with a common protocol, overseen by external experts. We estimated 1-year and 5-year relative survival, constructing 252 complete life tables to control for background mortality by age, sex, and calendar year. We report age-specific and age-standardised relative survival at 1 and 5 years, and 5-year survival conditional on survival to the first anniversary of diagnosis. We also examined incidence and mortality trends during 1985-2005. Relative survival improved during 1995-2007 for all four cancers in all jurisdictions. Survival was persistently higher in Australia, Canada, and Sweden, intermediate in Norway, and lower in Denmark, England, Northern Ireland, and Wales, particularly in the first year after diagnosis and for patients aged 65 years and older. International differences narrowed at all ages for breast cancer, from about 9% to 5% at 1 year and from about 14% to 8% at 5 years, but less or not at all for the other cancers. For colorectal cancer, the international range narrowed only for patients aged 65 years and older, by 2-6% at 1 year and by 2-3% at 5 years. Up-to-date survival trends show increases but persistent differences between countries. Trends in cancer incidence and mortality are broadly consistent with these trends in survival. Data quality and changes in classification are not likely explanations. The patterns are consistent with later diagnosis or differences in treatment, particularly in Denmark and the UK, and in patients aged 65 years and older. Department of Health, England; and Cancer Research UK.

12 September 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GSGunnar Steineck
Gunnar Steineck
FHFred Helgesen
Fred Helgesen
JAJan Adolfsson
Jan Adolfsson
PDPaul W. Dickman
Paul W. Dickman
JJJan-Erik Johansson
Jan-Erik Johansson
LHLars Holmberg
Lars Holmberg
We evaluated symptoms and self-assessments of quality of life in men with localized prostate cancer who participated in a randomized comparison between radical prostatectomy and watchful waiting. Between 1989 and 1999, a group of Swedish urologists randomly assigned men with localized prostate cancer to radical prostatectomy or watchful waiting. In this follow-up study, we obtained information from 326 of 376 eligible men (87 percent) concerning certain symptoms, symptom-induced distress, well-being, and the subjective assessment of quality of life by means of a mailed questionnaire. Erectile dysfunction (80 percent vs. 45 percent) and urinary leakage (49 percent vs. 21 percent) were more common after radical prostatectomy, whereas urinary obstruction (e.g., 28 percent vs. 44 percent for weak urinary stream) was less common. Bowel function, the prevalence of anxiety, the prevalence of depression, well-being, and the subjective quality of life were similar in the two groups. The assignment of patients to watchful waiting or radical prostatectomy entails different risks of erectile dysfunction, urinary leakage, and urinary obstruction, but on average, the choice has little if any influence on well-being or the subjective quality of life after a mean follow-up of four years.

27 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TIThe COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
The COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
RERosalind Eeles
Rosalind Eeles
TBThe Australian Prostate Cancer Bioresource
The Australian Prostate Cancer Bioresource
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
TCThe UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
The UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
DEDouglas F Easton
Douglas F Easton

1 August 2011 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PMPaul McGale
Paul McGale
SDSarah C. Darby
Sarah C. Darby
PHPer Hall
Per Hall
JAJan Adolfsson
Jan Adolfsson
NBNils-Olof Bengtsson
Nils-Olof Bengtsson
MEMarianne Ewertz
Marianne Ewertz

1 December 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
HGHenrik Grönberg
Henrik Grönberg
JAJan Adolfsson
Jan Adolfsson
MAMarkus Aly
Markus Aly
TNTobias Nordström
Tobias Nordström
PWPeter Wiklund
Peter Wiklund
MEMartin Eklund
Martin Eklund

1 September 2015 in European Urology
Verified
Journal Article
Open access
CBCecilia Bosco
Cecilia Bosco
ZBZsolt Bosnyak
Zsolt Bosnyak
AMAnders Malmberg
Anders Malmberg
JAJan Adolfsson
Jan Adolfsson
NKNancy L. Keating
Nancy L. Keating
Mieke Van HemelrijckMieke Van Hemelrijck
Mieke Van Hemelrijck
Whether androgen deprivation therapy (ADT) for men with prostate cancer (PCa) increases the risk of cardiovascular disease (CVD) remains controversial. Pooled analyses using data from randomised controlled trials suggest no increased risk of fatal CVD following ADT, but no pooled analyses exist for observational studies. To perform a meta-analysis using observational data on ADT and risk of CVD events in men with PCa. PubMed and Embase were searched using predefined inclusion criteria to perform meta-analyses on associations between types of ADT and nonfatal and fatal CVD outcomes using information from observational studies. Random effects meta-analyses were conducted to estimate relative risks (RRs) and 95% confidence intervals (CIs). A total of eight observational studies were identified studying at least one type of ADT and a nonfatal or fatal CVD outcome. The RR for risk of any type of nonfatal CVD was 1.38 (95% CI, 1.29-1.48) for men with PCa on gonadotropin-releasing hormone (GnRH) agonists, compared with men not treated with ADT. When analysing nonfatal ischemic heart disease only, the RR was 1.39 (95% CI, 1.26-1.54). The associations between GnRH agonists and nonfatal or fatal myocardial infarction or stroke were even stronger: RR: 1.57 (95% CI, 1.26-1.94) and RR: 1.51 (95% CI, 1.24-1.84), respectively. The results for other types of ADT in relation to the risk of any nonfatal CVD were RR: 1.44 (95% CI, 1.28-1.62) for orchiectomy and RR: 1.21 (95% CI, 1.07-1.367) for antiandrogens. Observational data show a consistent positive association between ADT and the risk of CVD. This finding supports the need for future randomised trials of PCa patients that include older patients and men with multiple comorbidities to better reflect the general population. We investigated all the available data from observational studies on hormonal treatment for prostate cancer and its possible cardiovascular adverse effects. We found consistent evidence that this treatment may increase the risk of cardiovascular disease.